AR120399A1 - Un método de tratamiento de un cáncer positivo para dll3 - Google Patents

Un método de tratamiento de un cáncer positivo para dll3

Info

Publication number
AR120399A1
AR120399A1 ARP200103072A ARP200103072A AR120399A1 AR 120399 A1 AR120399 A1 AR 120399A1 AR P200103072 A ARP200103072 A AR P200103072A AR P200103072 A ARP200103072 A AR P200103072A AR 120399 A1 AR120399 A1 AR 120399A1
Authority
AR
Argentina
Prior art keywords
dll3
positive cancer
treatment
dll3 positive
agent
Prior art date
Application number
ARP200103072A
Other languages
English (en)
Spanish (es)
Inventor
Marie Smit
Damiette - Soman Neelesh Ann
Vijay Vishesh Upreti
Mukul Minocha
Marc Anthony Yago
Michael Liao
Aditya Shetty
Sadraei Nooshin Hashemi
Gataree Ngarmchamnanrith
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR120399A1 publication Critical patent/AR120399A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
ARP200103072A 2019-11-10 2020-11-05 Un método de tratamiento de un cáncer positivo para dll3 AR120399A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19208214.7A EP3819312A1 (en) 2019-11-10 2019-11-10 Dosing regimen for anti-dll3 agents

Publications (1)

Publication Number Publication Date
AR120399A1 true AR120399A1 (es) 2022-02-09

Family

ID=68531385

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103072A AR120399A1 (es) 2019-11-10 2020-11-05 Un método de tratamiento de un cáncer positivo para dll3

Country Status (15)

Country Link
US (1) US20230174643A1 (enExample)
EP (2) EP3819312A1 (enExample)
JP (2) JP7709434B2 (enExample)
KR (1) KR20220097470A (enExample)
CN (2) CN120053637A (enExample)
AR (1) AR120399A1 (enExample)
AU (1) AU2020377981A1 (enExample)
CA (1) CA3156229A1 (enExample)
IL (1) IL292463A (enExample)
JO (1) JOP20220104A1 (enExample)
MX (1) MX2022005596A (enExample)
TN (1) TN2022000113A1 (enExample)
TW (1) TWI908743B (enExample)
UY (1) UY38948A (enExample)
WO (1) WO2021092134A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4482586A1 (en) * 2022-02-23 2025-01-01 Amgen Inc. Cancer treatment targeting dll3
CN121620371A (zh) * 2023-05-19 2026-03-06 勃林格殷格翰国际公司 T细胞衔接蛋白在治疗癌症中的用途
WO2025061132A1 (en) * 2023-09-21 2025-03-27 Concept To Medicine Biotech Co., Ltd. Anti-dll3 antibodies and uses thereof
TW202600599A (zh) * 2024-03-11 2026-01-01 大陸商樂普生物科技股份有限公司 抗ｄｌｌ３抗體及其用途
TW202602488A (zh) 2024-03-11 2026-01-16 美商安進公司 治療ｄｌｌ３陽性癌症受試者中腦轉移之方法
WO2026052061A1 (en) * 2024-09-05 2026-03-12 Nanjing Legend Biotech Co., Ltd. Adoptive cell compositions
WO2026060304A1 (en) 2024-09-13 2026-03-19 Amgen Inc. Subcutaneous administration of anti-dll3 agent for treatment of cancer
WO2026075950A1 (en) 2024-10-01 2026-04-09 Amgen Inc. Dosing regimen for anti-dll3 agent
CN120168667B (zh) * 2025-03-18 2026-04-14 中国科学院近代物理研究所 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
CN104520324A (zh) * 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
GB201302447D0 (en) * 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EP3337517A4 (en) * 2015-08-20 2019-04-17 Abbvie Stemcentrx LLC ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
CA3032820A1 (en) * 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
MA48763A (fr) * 2017-05-05 2020-04-08 Amgen Inc Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés

Also Published As

Publication number Publication date
JOP20220104A1 (ar) 2023-01-30
CN120053637A (zh) 2025-05-30
EP3819312A1 (en) 2021-05-12
TWI908743B (zh) 2025-12-21
JP2023501375A (ja) 2023-01-18
KR20220097470A (ko) 2022-07-07
CN114746117A (zh) 2022-07-12
AU2020377981A1 (en) 2022-05-26
CN114746117B (zh) 2025-02-28
EP4054636A1 (en) 2022-09-14
MX2022005596A (es) 2022-05-20
EP4054636A4 (en) 2024-01-03
JP7709434B2 (ja) 2025-07-16
US20230174643A1 (en) 2023-06-08
UY38948A (es) 2021-05-31
TW202128762A (zh) 2021-08-01
WO2021092134A1 (en) 2021-05-14
IL292463A (en) 2022-06-01
CA3156229A1 (en) 2021-05-14
TN2022000113A1 (en) 2024-01-02
JP2025148407A (ja) 2025-10-07

Similar Documents

Publication Publication Date Title
MX2022005994A (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.
UY38948A (es) Régimen de dosificación para agentes anti-dll3
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
ECSP045430A (es) Terapia de combinación para el tratamiento de cancer
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
PE20190351A1 (es) Agente terapeutico del sindrome de hunter y metodo de tratamiento
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
CO2021016606A2 (es) Métodos para administrar un anticuerpo anti-cd38 para tratar el mieloma múltiple
MX2024005237A (es) Compuesto que tiene actividad de degradacion de la proteina btk, y usos medicos del mismo.
AR111491A1 (es) Métodos para tratar enfermedades pediátricas
AR119430A1 (es) Métodos para tratar o prevenir la atrofia muscular espinal
MX2025005378A (es) Metodos para el tratamiento de enfermedades cardiovasculares
MX2022012353A (es) Metodos para el inicio de la dosis de los tratamientos con aripiprazol.
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
Aziz-Jalali et al. Efficacy of intralesional bleomycin in the treatment of resistant warts
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
CO2022015272A2 (es) Medicamento/agente para el tratamiento de coronavirus, infecciones retrovirales y hepatitis c

Legal Events

Date Code Title Description
FB Suspension of granting procedure